<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E03BB6BE-9D73-4FC5-9A57-65A62DAA55A3"><gtr:id>E03BB6BE-9D73-4FC5-9A57-65A62DAA55A3</gtr:id><gtr:name>Renal Association</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Clinical Science at North Bristol</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E03BB6BE-9D73-4FC5-9A57-65A62DAA55A3"><gtr:id>E03BB6BE-9D73-4FC5-9A57-65A62DAA55A3</gtr:id><gtr:name>Renal Association</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A0D018F9-FF04-4E19-9699-9089444CDD67"><gtr:id>A0D018F9-FF04-4E19-9699-9089444CDD67</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Mathieson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G9721265"><gtr:id>EC5F9236-5892-4740-8794-88012E3F47FD</gtr:id><gtr:title>Immunosuppression for progressive membranous nephropathy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9721265</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Idiopathic membranous nephropathy (IMN) is a form of glomerulonephritis which accounts for one quarter of cases of the nephrotic syndrome in adults and is an important cause of end-stage renal failure (ESRF). The condition has a variable natural history with many patients having spontaneous remissions, and there is no consensus on the value of immunosuppressive therapy. We have designed a prospective multicentre randomised controlled trial to test the hypothesis that imunosuppressive treatment can preserve renal function in the subset of patients with IMN who have the greatest risk of development of ESRF. This subset will be identified by monitoring excretory renal function; patients whose renal function is deteriorating will be randomised to one of three treatment groups: prednisolone plus chlorambucil; cyclosporin; or supportive treatment alone. Patients will be followed up for five years; the primary outcome measure will be further deterioration in renal function, secondary outcome measures will be effect on proteinuria and adverse effects. We estimate that in order to detect a halving of the risk of further deterioration in renal function with a powerof 0.9 we will need 40 patients in each group, total 120. An extensive consultation exercise amongst consultant members of the UK Renal Association has shown that there is widespread support for the trial, with over 80 nephrologists in up to 50 renal units indicating willingness to enter patients. We aim to complete recruitment within two years, the trial therefore taking 7 years for completion. We are requesting support for two half-time posts for the entire 7 year period: one research nurse and one clerical assistant, plus a further three research nurses for the two year recruitment phase. The trial will be monitored by a steering committee with an independent chairman and with formal statistical advice.</gtr:technicalSummary><gtr:fund><gtr:end>2009-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1999-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>437746</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Initial funding contribution</gtr:description><gtr:id>26948CB0-A9A1-41EA-ABBA-38E3E57D573B</gtr:id><gtr:impact>Regular updates have been provided and incorporated by Novartis into data monitoring for its product cyclosporin, one of the treatments being studied in the trial.</gtr:impact><gtr:outcomeId>47BBDB53E38-1</gtr:outcomeId><gtr:piContribution>Novartis provided some unrestricted pump-priming funding in the early stages of establishing the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Renal Association</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Renal Association &amp;amp; numerous renal units nationally</gtr:description><gtr:id>05C45702-3048-4824-A944-74F2356E1A35</gtr:id><gtr:impact>Recruitment completed, albeit not quite to original target.</gtr:impact><gtr:outcomeId>86260DB04DF-1</gtr:outcomeId><gtr:partnerContribution>Renal Association endorsement of the trial helped publicity and recruitment. Regular time on the programme of annual conferences to provide updates ensured that the trial was publicised and momentum was maintained.</gtr:partnerContribution><gtr:piContribution>Multi-centre trial depended upon partnership with the Renal Association (national specialty society for nephrology) and numerous members thereof, nephrologists who randomised their patients. Also numerous research nurses who provided patient information and supplied data.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Kidney patient association</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>C2102422-34AA-41C2-812E-7C4200DE37EB</gtr:id><gtr:impact>Invited speaker at national kidney patient conference, including publicising clinical trial

Improved patient and carer awareness of this trial and of clinical trials in general plus some of the issues surrounding them</gtr:impact><gtr:outcomeId>884ACD3392D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clinical trials sessions</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>EB9D71B6-406D-43AF-BA70-223F5585009C</gtr:id><gtr:impact>Several occasions: this trial has been a flagship for the Renal Association in the UK and progress reports have featured prominently in clinical trials sessions of conferences

Improved recruitment &amp;amp; support for the trial</gtr:impact><gtr:outcomeId>F8033F037F8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National and international conference presentations of results</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>A37AC93D-1FBF-4B1F-8923-3D151E741D85</gtr:id><gtr:impact>The trial provides an evidence-base that was previously missing and has already started to influence clinical practice internationally as evidenced by various communications that I have received.</gtr:impact><gtr:outcomeId>g5jwwokSagH</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>CD15F2D6-0C67-495C-983F-DBF846E64A58</gtr:id><gtr:title>Membranous nephropathy.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d26e945c75d415173d492286c7352c33"><gtr:id>d26e945c75d415173d492286c7352c33</gtr:id><gtr:otherNames>Mathieson PW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>pm_16260_20_23101149</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F80DE0FF-A842-438C-B333-3679F7DD8DF8</gtr:id><gtr:title>Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a48e3af29ccdf9e7d24ee9dfe06090a"><gtr:id>5a48e3af29ccdf9e7d24ee9dfe06090a</gtr:id><gtr:otherNames>Stanescu HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>CNRGHoPd2Dj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7E23DF7-3CCF-41FB-ADEC-B7E21D140043</gtr:id><gtr:title>Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a04eafca6d0aecc2742800a0f07937fb"><gtr:id>a04eafca6d0aecc2742800a0f07937fb</gtr:id><gtr:otherNames>Howman A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_16260_20_23312808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9989067C-D7D0-447E-9010-B32BF0EBEE73</gtr:id><gtr:title>Is low-dose ciclosporin an effective treatment for membranous nephropathy with nephrotic syndrome?</gtr:title><gtr:parentPublicationTitle>Nature clinical practice. Nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d26e945c75d415173d492286c7352c33"><gtr:id>d26e945c75d415173d492286c7352c33</gtr:id><gtr:otherNames>Mathieson PW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1745-8323</gtr:issn><gtr:outcomeId>74F761186B3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31E866D7-0132-498E-9D43-86930D1FC4AC</gtr:id><gtr:title>Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1acc6e64b57b7aa8b59e7cd7e99775c"><gtr:id>f1acc6e64b57b7aa8b59e7cd7e99775c</gtr:id><gtr:otherNames>Coenen MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>pm_16260_20_23431073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>914A7A53-2809-43CB-B6A3-56842C629CDF</gtr:id><gtr:title>Immunosuppression for membranous nephropathy - Authors' reply.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d26e945c75d415173d492286c7352c33"><gtr:id>d26e945c75d415173d492286c7352c33</gtr:id><gtr:otherNames>Mathieson PW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_16260_20_23791342</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9721265</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>